Interviste
14
Durvalumab improves long-term outcome in TNBC: Results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer
227
Evaluation of intra-tumoral SD-101 and pembrolizumab in combination with paclitaxel followed by AC in high-risk HER2- stage II/III breast cancer: Results from the I-SPY 2 trial
14
Che ruolo hanno gli inibitori di CDK4/6 nel trattamento del carcinoma della mammella luminal-like metastatico? Le nuove evidenze ci forniscono degli indizi sul loro inserimento rispetto alle linee precedenti e successive?
409
Ci sono nuovi spunti relativi a biomarcatori finalizzati all’individuazione di sottogruppi candidabili a un trattamento immunoterapico di prima linea nella patologia triple negative?
14
Outcomes in patients aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
281
PALOMAGE, a French real-world cohort of elderly women beyond age 70 with advanced breast cancer receiving palbociclib: Baseline characteristics and safety evaluation
